导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.93% | 4302/4773 |
| 近一周 | -7.03% | 5431/5462 |
| 近一月 | -6.26% | 3491/5421 |
| 近一季 | -4.23% | 1562/5209 |
| 近半年 | -22.89% | 4554/4920 |
| 近一年 | -23.02% | 4002/4366 |
| 近两年 | 40.24% | 1886/2954 |
| 近三年 | 7.24% | 1802/2253 |
| 成立以来 | 4.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.04% 2073/4961 |
-17.01% 4755/5312 |
- - |
- - |
| 2025 | 28.51% 1479/4813 |
5.38% 787/3635 |
5.16% 643/4076 |
23.29% 1555/4524 |
-5.94% 3649/4813 |
| 2024 | 7.16% 1684/3463 |
2.06% 823/2808 |
-17.14% 2746/3014 |
21.44% 581/3129 |
4.34% 718/3463 |
| 2023 | 20.55% 19/2656 |
40.94% 23/2280 |
5.97% 54/2385 |
-13.94% 2169/2515 |
-6.21% 1667/2655 |
| 2022 | -30.19% 1624/2207 |
-22.30% 1694/1919 |
-3.74% 1838/2016 |
-17.91% 1658/2113 |
13.69% 95/2208 |
| 2021 | -0.67% 758/1822 |
-8.59% 1090/1255 |
1.38% 1056/1330 |
-12.88% 1321/1466 |
23.03% 14/1822 |
| 2020 | 3.44% 912/1250 |
-5.34% 410/1028 |
19.94% 289/1067 |
1.40% 1023/1164 |
-10.15% 1164/1184 |
| 2019 | 27.46% 545/1092 |
33.70% 135/754 |
-17.35% 788/804 |
3.66% 242/850 |
11.27% 70/918 |
| 2018 | - - |
- - |
- - |
- - |
-8.35% 89/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证传媒ETF VS. 长安沪深300非周期A(740101) |